**13. References**


Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy 191

Cobleigh, M., Vogel, C., Tripathy, D., Robert, N., Scholl, S., & Fehrenbacher, L. (1999).

Colcher, D., Minelli, MF., Roselli, M., Muraro, R., Simpson-Milenic, D., & Schlom, J. (1988).

generation monoclonal antibodies. *Cancer Research*, Vol. 48, pp. 4597-4603. Cook, GJR. (2003). Oncological molecular imaging: nuclear medicine techniques. *British* 

Cornelissen, B., & Vallis, KA. (2010). Targeting the Nucleus: An Overview of Auger-Electron

Costelloe, CM., Rohren, EM., Madewell, JE., Hamaoka, T., Theriault, RL., Tse-Kuan, Y.,

Dearling, JLJ., & Pedley, RB. (2007). Technological Advances in Radioimmunotherapy.

Denardo, GL., Schlom, J., Buchsbaum, DJ., Meredith, RF., Odonoghue, JA., Sgouros, G.,

Denardo, SJ., Mirick, GR., Kroger, LA., O'Grady, LF., Erickson, KL., Yuan, A., Lamborn, KR.,

Disis, ML., Calenoff, E., & McLaughlin, G. (1994). Existent T-cell and antibody immunity to

Disis, ML., Pupa, SM., Gralow, JR., Dittadi, R., Menard, S., & Cheever, MA. (1997). High-

Einat, ES., & Moshe, I. (2010). PET in women with high risk for breast or ovarian cancer ,

Eniu, A. (2007). Integrating biological agents into systemic therapy of breast cancer: Trastuzumab, lapatinib, bevacizumab. *J BUON*, Vol. 12, pp. 119-26. Fass, L. (2008). Imaging and cancer: A review.*Molecular oncology*, Vol. 2, pp. 115–152.

Ferro-Flores, G., Ramírez, M., Melendez-Alafort, L., & Santos-Cuevas, CL. (2010). Peptides

Frangioni, JV. (2008). New technologies for human cancer imaging. *Journal of clinical* 

Friedman, M., et al. (2009). Engineering and characterization of a bispecific HER2xEGFR-

for *In Vivo* Target-Specific Cancer Imaging. *Mini-Reviews in Medicinal Chemistry,* 

binding affibody molecule. *Biotechnology and Applied Biochemistry.* Vol. 54, pp. 121–

stage breast cancer. *Journal of clinical Oncology,* Vol. 15, pp. 3363–3367.

for fractionated radioimmunotherapy. *Cancer,* Vol*.*94, pp.1332–1348. Denardo, S J. (2005). Functional Imaging: Radioimmunodetection and Therapy of Breast

Cancer. *Seminars in Nuclear Medicine*, Vol. 35, pp. 143-151.

Ehrlich, P. (1906). Collected Studies on Immunology, *John Wiley.* 

*Lancet Oncology*, Vol. 11, pp. 899–905.

*Oncology*, Vol. 26(24), pp. 4012-4021.

Vol.10, pp. 87-97.

131.

chimeric L6 radioimmunotherapy. *Cancer*,Vol. 73, pp. 1023–32.

Radionuclide Therapy. *Current Drug Discovery Technologies,*Vol. 7.

*Oncology*, Vol. 17, pp. 2639–48.

14.

20.

*Journal of Radiology*, Vol. 76, pp. 152-158.

*Clinical Oncology*, Vol. 19, pp. 457-469.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *Journal of clinical* 

Radioimmunolocalisation of human carcinoma xenografts with B72.3 second

Lewis ,VO., & Jingfei, M. (2009). Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. *Lancet Oncology*, Vol. 10, pp. 606–

Humm, JL., & DeNardo, SJ. (2002). Rationales, evidence, and design considerations

Hellstrom, I., Hellstrom, KE., & Denardo, GL. (1994). The biologic window for

HER-2/*neu* protein in patients with breast cancer. *Cancer Research*, Vol. 54, pp.16–

titer HER-2/*neu* protein-specific antibody can be detected in patients with early-


Begent, RHJ., Bagshawe, KD., & Pedley, RB. *(*1987). Use of second antibody in

Behr, TM., Sharkey, RM., Juweid, ME., Blumenthal, RD., Dunn, RM., & Griffiths, GL. (1995).

cationic amino acids and their derivatives, *Cancer Research*, 55(17):3825–34. Behr, TM., Sharkey, RM., & Juweid, ME. (1997). Variables influencing tumor dosimetry in

monoclonal antibodies. *The Journal of Nuclear Medicine,* vol. 38, pp. 409-418. Berg, JR., Kalisher, L., & Osmond, JD. (1973). Technetium-99m- disphosphonate concentration in primary breast cancer. *Radiology*, Vol. 109, pp. 393-394. Berg, WA., Gutierrez, L., NessAiver, MS., Carter, WB., Bhargavan, M., & Lewis, RS. (2004).

Boswell, C., Andrew, C., Brechbiel, & Martin, W. (2007).Development of

Brem, RF., Rapelyea, JA., & Zisman, G. (2005). Occult breast cancer: Scintimammography

Buchsbaum, D., Khazaelli, MB., & Liu, T. (1995). Fractionated radioimmunotherapy of

Bue, P., Holmberg, AR., Marquez, M., Westlin, JE., Nilsson, S., & Malmstrom, PU. (2000).

Capala, J., Kramer-Marek, G., Lee, S., Hassan, M., Kiesewetter, DO., Puri, A., Chernomordik,

Carl, AK., Borrebaeck, & Roland, C. (2001). Human therapeutic antibodies. *Current Opinion* 

Carlos, M., Mery, MPH., Bilal, M., Shafi, MSE., & Gary, B. (2006). Molecular imaging and radioimmunoguided surgery. *Seminars in Pediatric Surgery* ,Vol. 15, pp. 259-266. Carlssona, J., Aronssonb, EF., Hietalac, SO., Stigbrandd, T., & Tennvall, J. (2003). Tumor

Chang, CH., Sharkey, RM., Rossi, EA., Karacay, H., McBride, W., Hansen, HJ., Chatal, JF.,

Cleator, S., Heller, W., & Coombes, RC. (2007). Triple-negative breast cancer: therapeutic

epithelial mucin MoAb (BrE-3). *Cancer*, Vol. 5, pp. 38–44.

bladder cancer. *European Urology*, Vol. 38, pp. 584–589.

*Medicine and Biology*, Vol. 34, pp. 757–778.

breast cancer. *Radiology*, Vol. 237, pp. 274-80.

*Cancer Research,* Vol. 55, pp. 5881-5887.

*in Pharmacology*, Vol. 1, pp. 404–408.

options. *Lancet Oncology*, Vol. 8, pp. 235–44.

*Oncology*,Vol. 66, pp. 107–117.

Supplement 1

1(7), pp.553-563.

59–61.

radioimmunotherapy. *Journal of the National Cancer Institute Monographs*, Vol. 3, pp.

Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by

radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin

Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. *Radiology*, Vol. 233(3), pp.830-849. Berghammer, P., Obwegeser, R., & Sinzinger, H. (2001). Nuclear medicine and breast cancer: a review of current strategies and novel therapies. *The Breast,* Vol. 10, pp. 184-197. Blank, EW., Pant, KD., Chan, CM., Peterson, JA., & Ceriani, RL. (1992). A novel anti-breast

radioimmunotherapeutic and diagnostic antibodies: an inside-out view. *Nuclear* 

with high-resolution breast-specific gamma camera in women at high risk for

human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.

Intravesical administration of EGF-dextran conjugates in patients with superficial

V., Gandjbakhche, A., Griffiths, G., & Blumentha, R. (2009). Molecular targeting of HER2 for diagnosis and therapy of breast cancer. *Cancer Research*, Vol. 69,

therapy with radionuclides: assessment of progress and problems. *Radiotherapy and* 

Barbet, J., & Goldenberg, DM. (2002). Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. *Molecular Cancer Therapeutics,* Vol.


Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy 193

Guadagni, F., Witt, PL., & Robbins, PF. (1990). Regulation of carcinoembryonic antigen

Hamoudeh, M., Kamleh, MA., Diab, R., & Fessi, H. (2008). Radionuclides delivery systems

Harris, M. (2004). Monoclonal antibodies as therapeutic agents for Cancer. *Monoclonal* 

Hassan, MS., Ansari, J., Spooner, D., & Hussain, SA. (2010). Chemotherapy for breast cancer

Hawrysz, DJ., & Sevick-Muraca, EM. (2000). Developments toward diagnostic breast cancer

Hicke, BJ., Stephens, AW., Gould, T., Chang, YF., Lynott, CK., Heil, J., Borkowski, S., Hilger,

Hind, D., Ward, S., De Nigris, E., Simpson, E., Carroll, C., & Wyld, L. (2007). Hormonal

Hong, H., Sun, J., & Cai, W. (2008). Radionuclide-Based Cancer Imaging Targeting the

Hou, D., Hoch, H., & Johnston, GS*. (*1984). A new 111In-bleomycin complex for tumor

Howell, LP., Denardo, SJ., Levy, N., Lund, J., &Denardo, GL. (1995). Immunohistochemical

Huang, S., Armstrong, EA.,Benavente, S. (2004). Dual-agent molecular targeting of the

Hudson, PJ., & Kortt. (1999). High avidity scFv multimers; diabodies and triabodies.

Imai, K., & Takaoka, A. (2006). Comparing antibody and small-molecule therapies for

Izumi,Y., Xu, L., di Tomaso, E., Fukumura, D., Jain, RK. (2002). Tumour biology: herceptin

Jalilian, AR., Aboudzadeh, R., Akhlaghi, M., Shirazi, B., Moradkhani,S.,&Salouti, M. (2007).

Jalilian, AR., Akhlaghi, M., ShiraziB., Aboudzadeh, R., Salouti, M., Babaii, MH. (2006). [201 TI] (III)- Bleomycin for tumor imaging. *Radiochima Acta,* Vol. 94, pp. 453-459. Jonathan, D., Cheng, PT., Rieger M Von., Mehren, G., Adams, P., Louis, m., & Ws, N. (2000).

Jones, KL., & Buzdar, AU. (2004). A review of adjuvant hormonal therapy in breast cancer.

tyrosine kinase inhibitor. *Cancer Research,* Vol.64, pp. 5355-5362.

acts as an anti-angiogenic cocktail. *Nature*, Vol. 416, pp. 279–280.

*Compounds and Radiopharmaceuticals*, Vol. 50, pp.556–557.

Carcinoembryonic Antigen. *Biomarker Insights,* Vol. 3, pp. 435–451.

*Research*, 50: 6248–6255.

Vol. 60, pp. 1329–1346.

*Neoplasia*, Vol. 2(5), pp. 388-417.

*Health Technol Assess*, Vol. 11, pp. 1-134.

*Surgical Oncology*, Vol. 25, pp. 168-75.

*Immunological Methods,* Vol. 231, pp. 177-189.

*Seminars in Oncology Nursing*, Vol. 16, pp. 2-12.

*Endocrine-Related Cancer,* Vol. 11, pp. 391-406

cancer. *Nature,* Vol*.* 6, pp. 714-727.

*Markers*, Vol. 10, pp. 126–35.

*antibodies in cancer therapy,* Vol. 5, pp. 292–302.

(Review). *Oncology Reports*, Vol. 5, pp. 1121-31.

*The Journal Of Nuclear Medicine,* Vol.47(4), pp. 668-678.

expression in different human colorectal tumor cells by interferon-gamma, *Cancer* 

for nuclear imaging and radiotherapy of cancer. *Advanced Drug Delivery Reviews*,

imaging using near-infrared optical measurements and fluorescent contrast agents.

CS., Cook, G., Warren, S., & Schmidt, PG. (2006). Tumor targeting by an aptamer.

therapies for early breast cancer: systematic review and economic evaluation.

imaging: preparation, stability, and distribution in glioma-bearing mice. *Journal of* 

staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. *International Journal of Biological* 

epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with

Production and biological evaluation of [201Tl(III)]bleomycin*. Journal of Labelled* 

Recent advaces in immunotherapy and monoclonal antibody treatment of cancer.


Gaffer, SA., Pant, KD., & Shochat, D. (1981). Experimental studies of tumor

Gasparini, G.,Longo, R., Torino, F., & Morabito, A. (2005). Therapy of breast cancer with

Gianni, L., Llado, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, PL., & Cameron, DA.

Glasspool, RM., & Evans, TRJ. (2000). Clinical imaging of cancer metastasis. *European Journal* 

Goel, A., Augustine, S., & Baranowska-Kortyewicz, J. (2001). Singledose versus fractionated

Goel, A., Baranowska-Kortylewicz, J., Hinrichs, SH., Wisecarver, J., Pavlinkova, G.,

Gold, P., & Freedman, SO. (1965). Specific carcinoembryonic antigens of the human digestive system. *The Journal of Experimental Medicine,* Vol. 122, pp. 467–481. Goldenberg, DM., & Nabi, HA. (1999). Breast Cancer Imaging With Radiolabeled Antibodies. *Seminars in Nuclear Medicine*, Vol. XXIX, No 1, pp. 41-47. Goldenberg, DM., Deland, F., & Kim, E. *(*1978). Use of radiolabeled antibodies to

(CEA) and colon-specific antigen. *cancer*, Vol. 27, pp. 101-5.

1131-7.

*of Cancer,*Vol. 36, pp. 1661-1670.

*Molecular Imaging,* Vol. 54, pp. 574-81.

*Nuclear Medicine and Biology*, Vol . 18, pp. 413–24.

Vol. 7, pp. 175-184.

1519-1527.

radioimmunodetection using antibody mixtures against carcinoembryonic antigen

molecular targeting agents. *European Society for Medical Oncology*, Vol. 16, pp. 28-36.

(2010). Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. *Journal of clinical Oncology,* Vol. 28, pp.

radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain Fvs. *clinical Cancer Research,* Vol. 7, pp. 175-184. Goel, A., Augustine, S., Baranowska-Kortylewicz, J., & Colcher, D. *(*2001). Single-Dose

versusFractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs1. *clinical Cancer Research*,

Augustine, S., Colcher, D., Booth, BJ., & Batra, SK. (2001). 99mTc-labeled divalent and tetravalent CC49 single-chain Fvs: Novel imaging agents for rapid *in vivo*  localization of human colon carcinoma. *The Journal Of Nuclear Medicine, Vol.* 42, pp.

carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. *New England Journal of Medicine*, Vol. 298, pp. 1384–6. Goldenberg, DM., Goldenberg, H., Sharkey, RM. *(*1990)*.* In-vivo antibody imaging for the detection of human tumors. *Cancer Treatment Research*, Vol. 51, pp. 273–92. Goldsmith, J., & Signore, A. (2010). An overview of the diagnostic and therapeutic use of

monoclonal antibodies in medicine. *The Quarterly Journal of Nuclear Medicine And* 

radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery. *International journal of radiation applications and instrumentation Part B,* 

Gomes, CM., Abrunhosa, AJ., Ramos, P., & Pauwels, EKJ. (2010). Molecular imaging with SPECT as a tool for drug development. *Advanced Drug Delivery Reviews*. pp. 1-8. Granowska, M., Mather, SJ., & Britton, KE. (1991). Diagnostic evaluation of 111In and 99mTc

Gruaz-Guyon, A., Raguin, O., & Barbet, J. (2005). Recent advances in pretargeted radioimmunotherapy. *Current Medicinal Chemistry*, Vol. 12, pp. 319-338.


Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy 195

Liu, X., Pop Laurentiu, M., & Vitetta, Es. (2008). Engineering therapeutic monoclonal

Lorraine, MF., Raya, SB., Lisa von M., Henry, DA., Ralph., S, Jay, H.,&David, A. (1998).

Madsen, MT. (2007). Recent advances in SPECT imaging. *The Journal of Nuclear Medicine*,

Meel , R., Gallagher, WM., Oliveira, S., O'Connor, AE., Schiffelers, R M., & Byrne, AT.

Merkle, Van D. (2009). Blood Testing: Three Easy Steps. *Dynamic Chiropractic nutritional* 

Milenic, DE., Schlom, J., & Siler, K. (1991). Monoclonal antibody-based therapy of a human

Mohammadnejad, J., Rasaee, MJ.*,* Babaei, MH., & Salouti, M.(2010). Radioimmunotherapy of

Mohammadnejad, MJ., Rasaee, J., Babaei, MH., Paknejadc. M., Zahir, MH., & Salouti, M.

Mukhopadhyay, P., & Chakraborty., S. (2011). Mucins in the pathogenesis of breast cancer: Implications in diagnosis, prognosis and therapy. *Biochimica et Biophysica Acta,* Munagala, R., Aqil, F., & Gupta, RC. (2011). Promising molecular targeted therapies in

Munninka, THO., Nagengasta, WB., Brouwersb, AH., Schr odera, CP., Hospersa, GA.,

Murray, JL., Green, MC., & Hortobagyi, GN. (2000). Monoclonal antibody therapy for solid

Neves, AA., & Brindle, KM. (2006). Assessing responses to cancer therapy using molecular

Nguyen, BD., Roarke, MC., Karstaedt, PJ., Ingui, CJ., & Ram, PC. (2009). Practical

Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B., & Rutqvist, LE. (2002).

breast cancer. *Indian Journal of Pharmacology*, Vol. 43, pp. 236-45.

tumors. *Cancer treatment reviews,* Vol. 26, pp. 269–286.

randomised trials*. Lancet*, Vol. 359(9310), pp. 909-919.

imaging. *Biochimica et Biophysica Acta*, Vol. 1766, pp. 242–261

bench to bedside technologies. *Drug Discovery Today*,Vol. 15.

*Clinical Cancer Research,* Vol*. 11, pp.* 5215-5220

breast cancer. *The Breast*.Vol. 16, pp. 120–129.

Vol. 48 (4), pp. 661–673.

*wellness*, Vol. 5, No. 2, pp.1-3.

Vol. 51, pp. 2889-2896.

19, pp. 15–25.

Vol. 19, pp. 79–88.

breast cancer. *The Breast,* pp. 66–73

*diagnostic radiology,* Vol. 38, pp. 68-83.

antibodies. *Immunological Reviews*, Vol. 222, pp. 9–27

Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab.

Immunolymphoscintigraphy in Breast Cancer:valuation Using 131I-Labeled Monoclonal Antibody B72.3. *Nuclear Medicine and Biology*, Vol. 25, pp. 251–260. Luini, A., Gatti, G., & Zurrida, S. (2007). The evolution of the conservative approach to

(2010). Recent advances in molecular imaging biomarkers in cancer: application of

tumor xenograft with a 177-lutetium-labeled immunoconjugate. *Cancer Research,* 

MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: Comparison of direct and indirect radioiodination methods, *Human Antibodies*, Vol.

(2010). A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: Labeling of antibody and its quality control, *Human Antibodies,*

Hoogec, MN., Lub-de, WE., Dieste, PJ., & Vries, EGE. (2009). Molecular imaging of

Applications of Nuclear Medicine in Imaging Breast Cancer. *Current problems in* 

Long-term effects of mammography screening: updated overview of the Swedish


Jones, PT., Dear, PH., Foote, J., Neuberger, MS., & Winter, G. (1986). Replacing the

Kepshire, DS., Davis, SC., Dehghani, H., Paulsen, KD., Pogue, BW. (2007). Subsurface

Keshtgar, M., Davidson, T., Pigott, K., Falzon, M., & Jones, A. (2010). Current status and

Kohler, G., & Milstein, C. (1978). Continuous culture of fused cells secreting antibody for the

Kohler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of

Kopans, DB. (1992). The positive predictive value of mammography. *American Journal of* 

Koppe, MJ., Postema, EJ., & Aarts, F. (2005). Antibody-guided radiation therapy of cancer.

Kortt, AA., Dolezal, O., Power, BE., & Hudson, PJ. (2001). Dimeric and trimeric antibodies:

Kraeber–Bodere, F., Goldenberg, DM., Chatal,JF., & Barbet,J. (2009). Pretargeted

Kramer, EL., Denardo, SJ., Liebes, L., Kroger, LA., Noz, ME., Mizrachi, H., Salako, QA.,

Kubetzko, S., Balic, E., Waibel, R., Zangemeister-Wittke, U., & Pluckthun, A. (2006).

Larson, SM., Divgi, C., Scott, A., Daghighian, F., Macapilnac, H., & Welt, S. (1994). Current

Lawrence, LJ., Kortt, AA., Iliades, P., Tulloch, PA., & Hudson, PJ. (1998). Orientation of

Liberman, L. (2000). Percutanous imaging-guided core breast biopsy:state of the art the millennium . *American Journal of Roentgenology*, Vol. 174. pp. 1191-1199. Lin, FI., & Iagaru, A. (2010). Current Concepts and Future Directions in

Lin, Y., Hung, G., Luo, T., Tsai, S., Sun, S., Hsia, C., Chen, S., & Lin,WY. (2007). Reducing

Linden, O., Hindorf, C., Cavallin-Stahl, E., Wegener, WA., Goldenberg, DM., Horne, H.,

Radioimmunotherapy. *Current Drug Discovery Technologies* 

high avidity scFvs for cancer targeting. *Biomolecular Engineering,* Vol. 18, pp. 95–

radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.

Furmanski, P., Glenn, SD., & Denardo, GL. (1993). Radioimmunolocalization of breast carcinoma using BrE-3 monoclonal antibody: phase I study. *The Journal Of* 

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment. D5:effects on tumor targeting. *The Journal of Biological Chemistry*, Vol. 281, pp.

Status of Radioimmunodetection. *Nuclear Medicine and Biology,*Vol. 21, pp. 721-729.

antigen binding sites in dimeric and trimeric single-chain Fv antibody fragments.

renal uptake of 111In-DOTATOC: A comparison among various basic amino acids ,

Ohisson, Tomas., Lars, S., Sven-Erik S., & Jan T. (*2005)*. Dose Fractionated

mouse. *Nature,* Vol. 321, pp. 522-5.

*England Journal of Medicine*, Vol. 298, pp. 1384-6.

*Roentgenology*, Vol. 158, pp. 521-526.

*Current Oncology,* Vol. 16(5), pp. 3–8.

*Nuclear Medicine*, Vol. 34, pp. 1067–74.

*FEBS Letters,* Vol. 425(3), pp. 479-484.

*Annals of Nuclear Medicine,* Vol. 21, pp. 79–83.

predefined specificity. *Nature,* Vol. 256, pp. 495–497.

*Cancer and Metastasis Reviews,* Vol.24, pp. 539–567.

pp.1669-1678.

8, pp. 199-202.

108.

35186–351201.

complementarity-determining regions in a human antibody with those from a

diffuse optical tomography can localize absorber and fluorescent objects but recovered image sensitivity is nonlinear with depth. *Applied Optics*, Vol.46 (10),

advances in management of early breast cancer. *International Journal of Surgery,* Vol.

detection and localization of diverse cancers by external photo scanning. *New* 

Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. *Clinical Cancer Research,* Vol*. 11, pp.* 5215-5220


Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy 197

Salouti, M., Babaei, MH., Rajabi, H.,& Foroutan, H. (2011). Comparison of 99mTc-labeled

Salouti, M., Rajabi, H., Babaei, MH., & Rasaee, MJ. (2008). Breast tumor targeting with

Salouti, M., Rajabi, H., & Babaei, MH. (2006). A new monoclonal antibody

Sauer, G., Deissler, H., Strunz, K., Helms, G., Remmel, E., & Koretz, K. (2005). Ultrasound-

Schillaci, O., & Buscombe, JR. (2004). Breast scintigraphy today: Indications and limitations. *European Journal of Nuclear Medicine and Molecular Imaging,* Vol. 31, pp. 35-45. Schillaci, O., Danieli, R., & Filippi, L. (2007). Scintimammography with a hybrid SPECT/CT

Schlom, J., Eggensperger, D., & Colcher D. (1992). Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. *Cancer Research*, Vol. 52, pp. 1067-1072. Schlom, J., Molinolo, A., & Simpson, JF. (1990). Advantage of dose fractionation in

Schueller, G., Schueller-Weidekamm, C., & Helbich, TH. (2008). Accuracy of

Sergey, MD., & Ekaterina, NL. (2008). Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. *BioEssays,* Vol. 30, pp.904–918. Sergides, G., Austin, RCT., & Winslet, MC. (1999). Radioimmunodetection: technical

Shahied, LS., Tang, Y., Alpaugh, RK., Somer, R., & Greenspon, D. (2004). Bispecific

Sharkey, RM., & Goldenberg, DM. (2006). Targeted Therapy of Cancer: New Prospects for

Sharkey, RM., & Goldenberg, DM. (2008). Novel radioimmunopharmaceuticals for cancer

Slamon, D., Eiermann, W., & Robert, N. (2006). 2nd interim analysis phase III randomized

cancer imaging. *Annals of Nuclear Medicine,* Vol. 25, pp. 87–92.

antibody and its quality control. *DARU,* Vol. 14, pp. 51-56.

Sawyers, C. (2004). Targeted cancer therapy*. Nature,* Vol. 432, pp. 294-297.

imaging system. *Anticancer Research*, Vol. 27, pp. 557-62.

*Medicine and Biology,* Vol. 35, pp. 763–768.

*Cancer,* Vol. 92(2), pp. 231-235.

82, pp. 763-771.

pp. 1761- 1773.

25, pp. 529–539.

pp. 53907–53914.

San Antonio, December 14–17*.*

243.

1316.

PR81 and its F(ab0)2 fragments as radioimmunoscintigraphy agents for breast

99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. *Nuclear* 

radiopharmacetical for radioimmunoscintigraphyof breast cancer: direct labeling of

guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumor classification. *British Journal of* 

monoclonal antibody-directed radioimmunotherapy. *National Cancer Institute*, Vol.

ultrasoundguided, large-core needle breast biopsy. *European Radiology,* Vol. 18(9),

problems and methods of improvement, *European Journal of Surgical Oncology*, Vol.

minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. *Biological Chemistry,* Vol. 279,

Antibodies and Immunoconjugates. *A Cancer Journal for Clinicians*, Vol. 56, pp. 226-

imaging and therapy*. Current Opinion in Investigational Drugs* ,Vol. 9(12), pp. 1302-

trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients*. Proceeding of Breast Cancer Symposium,* 


Olafsen, T., Tan, GJ., & Park, JM. (2004). Tumor targeting, biodistribution and micro-PET

Orlova, A., Magnusson, M., Eriksson, TL., Nilsson, M., Larsson, B., Hoiden-Guthenberg, I.,

Orlova, A., Nilsson, FY., Wikman, M., Widstrom, C., Stahl, S., Carlsson, J,. & Tolmachev, V.

Pagel, JM., Boferman, OC., Hazel, BB., & Ruby, F. (2009). Targeted radionuclide therapy of

Pedley, RB., Boden, JA., Boden, R., Dale, R., & Begent, RH. (1993). Comparative

Pontus, KE., Bforjessona, EJ., Postemab, R de B., Jan, C., Roosc, C., Rene L., Kalevi, JA.,

Pressman, D., & Korngold, L. (1953). The in-vivo localisation of anti-Wagner-osteogenic-

Pysz, MA., Gambhir, SS., Willmann, JK. (2010). Molecular imaging:currentstatusand

Rasaneh, S., Rajabi, H., Babaei, MH., Johari Daha, F., & Salouti, M. (2009). Radiolabeling of

Richman, CM., & Denardo, SJ., (2001). Systemic radiotherapy in metastatic breast cancer

Roland, B., Walter, OW., Press, & Pagel, JM. (2010). Pretargeted Radioimmunotherapy for

Ross,RJ., & Thompson, JS. (1982), Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials . *Radiology*, Vol. 143, pp. 195-205. Ross, JS., Fletcher, JA., Bloom, KJ., Linette, GP., Stec, J., Symmans, WF., Pusztai, L., &

Salouti, M., Babaei, MH., Rajabi, H., & Rasaee, MJ. (2011). Preparation and biological

and protein. *Molecular and Cellular Proteomics,* Vol. 3, pp. 379–398.

in a colonic xenograft model. *British Journal of Cancer,* Vol. 68, pp. 69-73. Perkins, AC., & Missailidis, S. (2007). Radiolabelled aptamers for tumor imaging and

mice. *The Journal Of Nuclear Medicine,,* Vol. 44, pp. 363-369.

*Journal Of Nuclear Medicine,* Vol. 47(3), pp. 512-519.

*Cancer Research*, Vol. 56, pp. 2123–2129.

*Hematology,* Vol. 38, pp. 25–35.

*Nuclear Medicine and Biology*, pp. 1-7.

sarcoma antibodies. *Cancer*, Vol. 6, pp. 619–623.

emerging strategies, *Clinical Radiology,* Vol. 65, pp. 500-506.

*Research,* Vol. 66, pp. 4339–4348.

pp. 292-296.

363–369.

25(2).

imaging of engineered anti-her2/Neu antibody fragments in xenograft-bearing

Widstrom, C., Carlsson, J., Tolmachev,V., Stahl, S., & Nilsson, F Y. (2006). Tumor imaging using a picomolar affinity HER2 binding affibody molecule. *Cancer* 

(2006). Comparative *in vivo* evaluation of technetium and iodine labels on an anti-HER-2 affibody for single-photon imaging of HER-2 expression in tumors. *The* 

cancer. *Principles of Cancer Biotherapy*, 463 © Springer Science + Business Media B.V.

radioimmunotherapy using intact or F(ab0)2 fragments of 131I anti-CEA antibody

therapy. *The Quarterly Journal Of Nuclear Medicine And Molecular Imaging,* Vol. 51(4),

Kairemod, Guus, AMS., van Dongen. (2004). Radioimmunodetection and radioimmunotherapy of head and neck cancer.*Oral Oncology*, Vol. 40, pp. 761–772. Press, OW., Shan, D., & Howell-Clark, J. (1996). Comparative metabolism and retention of

iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. *Nuclear Medicine and Biology*, Vol. 36, pp.

using 90Y-linked monoclonal MUC-1 antibodies. *Critical Reviews in Oncology:* 

Hematologic and Other Malignancies, *Cancer Biotherapy & Radiopharmaceuticals*.Vol.

Hortobagyi, GN. (2004). Targeted therapy in breast cancer: the HER- 2/neu gene

evaluation of 177Lu conjugated PR81 for radioimmunotherapy of breast cancer.


**8** 

*USA* 

**Diagnosis of Dementia Using** 

**Nuclear Medicine Imaging Modalities** 

Merissa N. Zeman, Garrett M. Carpenter and Peter J. H. Scott

*Department of Radiology, University of Michigan Medical School, Ann Arbor, MI,* 

Dementia describes the loss of brain function that occurs with certain diseases, and which has the potential to affect memory, thinking, language, judgment, and behavior. Most types of dementia involve irreversible neurodegeneration, and Alzheimer's disease (AD) is the most common form. Beyond AD however, there are many other diseases that can lead to dementia including dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Parkinson's disease with dementia, corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). Dementia can also be the result of many small strokes and, in such

Whilst such clinically and neuropathologically overlapping dementia diseases can be predicted by clinical diagnosis, definitively differentiating them from one another has typically been attempted using high-risk diagnostic procedures (e.g. brain biopsy, Lumbar puncture) or, more commonly, during a *post-mortem* examination. This makes it difficult to a) differentiate dementias and treat each appropriately before patient death; b) manage the diseases early, before the onset of cognitive decline; c) select appropriate patients for assisting in dementia-related drug development; and d) track the impact of new dementia therapeutics in clinical trials. Therefore, new non-invasive diagnostic methods for managing dementia are in high demand and, reflecting this, many radiopharmaceuticals (drugs tagged with a radioactive isotope) have been developed over the last 2 decades that allow noninvasive examination of dementia pathophysiology in living human subjects using nuclear medicine imaging techniques. Such techniques include positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, and have greatly enhanced diagnostic confidence across the entire dementia disease spectrum in recent years. This chapter reviews radiopharmaceuticals commonly employed clinically in the management of dementia patients, suffering from the diseases outlined above, with nuclear medicine modalities. The chapter is divided by disease entity, and progress in imaging the pathophysiology of each disease is highlighted. In addition to those radiopharmaceuticals with approval for human use discussed herein, there are many experimental radiopharmaceuticals for dementia in pre-clinical development, which have not yet been translated into clinical use. Comprehensive review of such pre-clinical radiopharmaceuticals is outside the scope of this book, and pertinent examples are highlighted only when necessary to indicate key concepts involved in imaging dementia patients. The interested reader can obtain additional information on radiopharmaceuticals currently in development

**1. Introduction** 

cases, is called vascular dementia.

